UroGen Pharma Ltd. acquires next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc.
Acquiring Company
UroGen Pharma
Acquired Company
IconOVir Bio
PrincetonSan DiegoBiotechnologyHealthcareBiotechnologyDescription
UroGen Pharma Ltd. expands its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. In addition, UroGen also announced strategic research collaborations to explore the potential of its proprietary RTGel technology to enhance clinical effectiveness of multiple immunotherapies.
Quick answer
UroGen Pharma is acquiring IconOVir Bio, announced February 20, 2025. UroGen Pharma is based in Princeton, New Jersey, United States.
- How much did UroGen Pharma pay for IconOVir Bio?
- The deal value was not disclosed.
- What does UroGen Pharma do?
- UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options.
- Where are UroGen Pharma and IconOVir Bio based?
- UroGen Pharma is based in Princeton, New Jersey, United States. IconOVir Bio is based in San Diego, California, United States.
- Who are the decision-makers at UroGen Pharma?
- Fundz holds 4 contacts at UroGen Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- AbbVie completes acquisition of Nimble Therapeutics to expand its immunology pipeline (January 23, 2025)
- Novartis completes acquisition of Anthos Therapeutics (April 4, 2025)
- Lupin acquires UK-based Renascience Pharma (April 3, 2025)
- Globus Medical completes acquisition of Nevro Corp. (April 3, 2025)
- Novartis acquires Anthos Therapeutics for $3.1B, $3.1B (April 3, 2025)
Who to call at UroGen Pharma, and when
When UroGen Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day UroGen Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at UroGen Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at UroGen Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment UroGen Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired IconOVir Bio?
IconOVir Bio was acquired by UroGen Pharma, based in Princeton. The deal was reported on February 20, 2025. UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. UroGen Pharma is publicly traded (URGN) and operates in Biotechnology.
When did UroGen Pharma acquire IconOVir Bio?
UroGen Pharma's acquisition of IconOVir Bio was reported on February 20, 2025. UroGen Pharma Ltd. expands its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does IconOVir Bio do?
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.